Anshul
@anshulg.bsky.social
Ex-engineer. PGY3 IM physician @ Mayo Clinic. Incoming Cardiology fellow @ Mayo Clinic. Amazing cat dad. Mediocre runner, guitarist, and cricket fanatic.
Reposted by Anshul
🆕 The ACC has released guidance on diagnosing and managing acute #myocarditis in adults, providing a streamlined framework based on recent clinical advancements.
Read the key points 🔗 bit.ly/4gwh4bu
#JACC #CardioSky #MedSky
@jaccjournals.bsky.social
Read the key points 🔗 bit.ly/4gwh4bu
#JACC #CardioSky #MedSky
@jaccjournals.bsky.social
December 11, 2024 at 7:00 PM
🆕 The ACC has released guidance on diagnosing and managing acute #myocarditis in adults, providing a streamlined framework based on recent clinical advancements.
Read the key points 🔗 bit.ly/4gwh4bu
#JACC #CardioSky #MedSky
@jaccjournals.bsky.social
Read the key points 🔗 bit.ly/4gwh4bu
#JACC #CardioSky #MedSky
@jaccjournals.bsky.social
Reposted by Anshul
A 3-year study of tirzepatide in participants with obesity and prediabetes showed substantial and sustained weight reduction and decreased risk of progression to diabetes with tirzepatide, as compared with placebo. Full SURMOUNT-1 trial results: nej.md/48VdDZp
#endosky #medsky
#endosky #medsky
Tirzepatide for Obesity Treatment and Diabetes Prevention | NEJM
Obesity is chronic disease and causal precursor to myriad other conditions, including
type 2 diabetes. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown
to provide substantial a...
nej.md
December 7, 2024 at 3:15 PM
A 3-year study of tirzepatide in participants with obesity and prediabetes showed substantial and sustained weight reduction and decreased risk of progression to diabetes with tirzepatide, as compared with placebo. Full SURMOUNT-1 trial results: nej.md/48VdDZp
#endosky #medsky
#endosky #medsky
